Virios Therapeutics announces dosing of first patient in IMC-2 Long-COVID treatment trial

Aug. 15, 2022
New long-COVID research program.

Virios Therapeutics, Inc. announced commencement of enrollment in its exploratory Long-COVID trial.

The trial will assess the safety and effectiveness of antiviral therapy with Virios’ second development combination, IMC-2 (valacyclovir + celecoxib), to treat the symptoms associated with Long-COVID, including fatigue, pain, sleep disruption, anxiety, depression and cognitive function and overall health improvement. IMC-2 is a novel, dual mechanism antiviral therapy combining valacyclovir and celecoxib designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden.

Read the full release on Businesswire